VanEck Pharmaceutical ETF (PPH) Dividend Yield, History & Forecast

VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund (ETF) listed on the NASDAQ. It pays a current dividend yield of 1.95% ($2.17 per share annually (TTM)). The most recent ex-dividend date was July 1, 2026, with payment scheduled for July 7, 2026. market capitalization is approximately $951M. Review PPH dividend history on this scorecard, compare peers in the Compare Dividend Returns tool, or project income with the dividend calculator.

PPH fund composition

PPH holds 26 positions, with 72.9% of assets in its ten largest. It charges an expense ratio of 0.36%, and manages $1.03B.

Top 10 holdings

HoldingWeight
LLYEli Lilly & Co18.54%
MRKMerck & Co Inc11.01%
NVSNovartis Ag10.44%
PFEPfizer Inc5.15%
BMYBristol-Myers Squibb Co4.97%
NVONovo Nordisk A/S4.96%
MCKMckesson Corp4.78%
ABBVAbbvie Inc4.51%
JNJJohnson & Johnson4.47%
GSKGsk Plc4.03%

Sector allocation

Healthcare100.0%Industrials0.1%

Frequently Asked Questions about VanEck Pharmaceutical ETF (PPH)

What is VanEck Pharmaceutical ETF's dividend yield?
VanEck Pharmaceutical ETF (PPH) pays a current trailing twelve-month dividend yield of 1.95%, which works out to $2.17 per share annually based on the most recent payout schedule.
When does VanEck Pharmaceutical ETF pay distributions?
The most recent ex-dividend date was July 1, 2026. The next scheduled dividend payment date is July 7, 2026.
How many years has VanEck Pharmaceutical ETF increased its dividend?
VanEck Pharmaceutical ETF (PPH) has increased its dividend for 3 consecutive years.
What does VanEck Pharmaceutical ETF invest in?
VanEck Pharmaceutical ETF (PPH) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.